Please login (Members) to view content or
(Nonmembers) this article.
No votes yet

Management of mTOR Inhibitor Side Effects

Patricia A. Creel
CJON 2009, 13(6), 19-23 DOI: 10.1188/09.CJON.S2.19-23

Although surgery remains the primary curative treatment for renal cell carcinoma (RCC), systemic therapy also is indicated in the advanced disease setting. This article reviews the role of mammalian target of rapamycin inhibitors in the treatment of metastatic RCC. A case study is presented to illustrate side-effect management issues commonly encountered by oncology nurses in clinical practice.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or